Publications

1. DeMarini D, Gwinn W, Watkins E, Reisfeld B, Chiu WA, Zeise L, et al. (2025). IARC workshop on the key characteristics of carcinogens: assessment of endpoints for evaluating mechanistic evidence of carcinogenic hazards. Environ Health Perspect. https://doi.org/10.1289/ehp15389 PMID:39899356
2. Berrington de González A, Masten SA, Bhatti P, Fortner RT, Peters S, Santonen T, et al. (2024). Advisory Group recommendations on priorities for the IARC Monographs. Lancet Oncol. 25(5):546–8. https://doi.org/10.1016/S1470-2045(24)00208-0 PMID:38621402
3. Middleton DRS, Wedekind R, Hall AL, Suonio E, DeBono NL, Vermeulen RCH, et al. (2024). Critical reviews of exposure assessment in carcinogenic hazard identification: the IARC Monographs experience. Occup Environ Med. 81(7):366–372. https://doi.org/10.1136/oemed-2023-109277 PMID:39033030
4. DeBono NL, Daniels RD, Beane Freeman LE, Graber JM, Hansen J, Teras LR, et al. (2023). Firefighting and cancer: a meta-analysis of cohort studies in the context of cancer hazard identification. Saf Health Work. 14(2):141–52. https://doi.org/10.1016/j.shaw.2023.02.003 PMID:37389311
5. M Filho A, Turner MC, Warnakulasuriya S, Richardson DB, Hosseini B, Kamangar F, et al. (2023). The carcinogenicity of opium consumption: a systematic review and meta-analysis. Eur J Epidemiol. 38(4):373–89. https://doi.org/10.1007/s10654-023-00969-7 PMID:36773182
6. Schubauer-Berigan MK (2023). Invited perspective: Good measure – assessing impact of cancer hazard identification on policies for cancer prevention. Environ Health Perspect. 131(12):121302. https://doi.org/10.1289/EHP14099 PMID:38088578
7. Turner MC, Cogliano V, Guyton K, Madia F, Straif K, Ward EM, et al. (2023). Research recommendations for selected IARC-classified agents: impact and lessons learned. Environ Health Perspect. 131(10):105001. https://doi.org/10.1289/EHP12547 PMID:37902675
8. Reisfeld B, de Conti A, El Ghissassi F, Benbrahim-Tallaa L, Gwinn W, Grosse Y, et al. (2022). kc-hits: a tool to aid in the evaluation and classification of chemical carcinogens. Bioinformatics. 38(10):2961–2. https://doi.org/10.1093/bioinformatics/btac189 PMID:35561175
9. Hodge JC, Netto GJ, Rekhi B, Cooper WA, Eden M, Field AS, et al. (2025). WHO Classification of Tumours: evolution of a global resource in the molecular era. Lancet Oncol. 26(4):410–3. https://doi.org/10.1016/S1470-2045(24)00709-5 PMID:40179904
10. Giesen C, Goldman-Levy G, Cree IA, Cierco Jimenez R, Machado A, Lokuhetty D (2024). WHO Classification of Tumours: moving towards the sixth edition. Histopathology. https://doi.org/10.1111/his.15325 PMID:39293942
11. Colling R, Indave I, Del Aguila J, Jimenez RC, Campbell F, Chechlińska M, et al. (2024). A new Hierarchy of Research Evidence for Tumor Pathology: a Delphi study to define levels of evidence in tumor pathology. Mod Pathol. 37(1):100357. https://doi.org/10.1016/j.modpat.2023.100357 PMID:37866639
12. Colling R, Indave I, Del Aguilla J, Cierco Jimenez R, Campbell F, Chechlinska M, et al. (2024). Moving forward on tumor pathology research reporting: a guide for pathologists from the World Health Organization Classification of Tumors Living Evidence Gap Map by Tumour Type Group. Mod Pathol. 37(7):100515. https://doi.org/10.1016/j.modpat.2024.100515 PMID:38763419
13. Shafique A, Gonzalez R, Pantanowitz L, Tan PH, Machado A, Cree IA, et al. (2024). A preliminary investigation into search and matching for tumor discrimination in World Health Organization breast taxonomy using deep networks. Mod Pathol. 37(2):100381. https://doi.org/10.1016/j.modpat.2023.100381 PMID:37939901
14. Cree IA (2023). The new WHO cytopathology reporting systems – extending the WHO classification of tumors. J Am Soc Cytopathol. 12(4):239–42. https://doi.org/10.1016/j.jasc.2023.04.004 PMID:37244847
15. Milman T, Grossniklaus HE, Goldman-Levy G, Kivelä TT, Coupland SE, White VA, et al.; WHO Classification of Tumours Editorial Board (2023). The 5th edition of the World Health Organization Classification of Tumours of the Eye and Orbit. Ocul Oncol Pathol. 9(3–4):71–95. https://doi.org/10.1159/000530730 PMID:37900189
16. Dossus L, Gunter MJ, Gonzalez-Gil EM, Lauby-Secretan B, Ahmadi, N, Hursting S, et al. (2025). CUP Global Framework for the review of the biological pathways linking diet, nutrition, body weight, and physical activity with cancer incidence. Health Open Research. https://doi.org/10.21955/healthopenres.1115016.1
17. Terry MB, English DR, Freudenheim JL, Lauby-Secretan B, Gapstur SM (2024). Alcohol cessation and breast cancer risk stratified by hormone receptor status. Breast Cancer Res. 26(1):179. https://doi.org/10.1186/s13058-024-01937-z PMID:39639353
18. Rumgay H, Nethan ST, Shah R, Vignat J, Ayo-Yusuf O, Chaturvedi P, et al. (2024). Global burden of oral cancer in 2022 attributable to smokeless tobacco and areca nut consumption: a population attributable fraction analysis. Lancet Oncol. 25(11):1413–23. https://doi.org/10.1016/S1470-2045(24)00458-3 PMID:39393386
19. Sohi I, Rehm J, Saab M, Virmani L, Franklin A, Sánchez G, et al. (2024). Alcoholic beverage consumption and female breast cancer risk: a systematic review and meta-analysis of prospective cohort studies. Alcohol Clin Exp Res (Hoboken). 48(12):2222–41. https://doi.org/10.1111/acer.15493 PMID:39581746
20. Gapstur SM, Bouvard V, Nethan ST, Freudenheim JL, Abnet CC, English DR, et al. (2023). The IARC perspective on alcohol reduction or cessation and cancer risk. N Engl J Med. 389(26):2486–94. https://doi.org/10.1056/NEJMsr2306723 PMID:38157507